BSE Live
Mar 24, 14:34Prev. Close
1559.15
Open Price
1573.60
Bid Price (Qty.)
1591.15 (1)
Offer Price (Qty.)
1594.25 (12)
NSE Live
Mar 24, 14:34Prev. Close
1560.30
Open Price
1604.00
Bid Price (Qty.)
1592.20 (24)
Offer Price (Qty.)
1593.70 (5)
| Key Financial Ratios of Caplin Point Laboratories (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 26.13 | 19.60 | 13.64 | 9.30 | 29.99 | |
| Diluted EPS (Rs.) | 25.95 | 19.50 | 13.57 | 9.30 | 29.99 | |
| Cash EPS (Rs.) | 28.73 | 22.35 | 16.04 | 11.06 | 34.83 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 79.31 | 57.13 | 39.10 | 26.48 | 82.33 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 79.31 | 57.13 | 39.10 | 26.48 | 84.80 | |
| Dividend / Share(Rs.) | 2.50 | 2.20 | 2.00 | 1.50 | 6.00 | |
| Revenue from Operations/Share (Rs.) | 69.78 | 70.99 | 56.42 | 45.19 | 153.07 | |
| PBDIT/Share (Rs.) | 36.09 | 29.56 | 21.84 | 14.02 | 43.54 | |
| PBIT/Share (Rs.) | 33.49 | 26.80 | 19.33 | 12.27 | 38.71 | |
| PBT/Share (Rs.) | 33.46 | 26.80 | 19.32 | 12.25 | 38.64 | |
| Net Profit/Share (Rs.) | 26.13 | 19.59 | 13.53 | 9.30 | 30.00 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 51.71 | 41.63 | 38.70 | 31.02 | 28.44 | |
| PBIT Margin (%) | 47.99 | 37.75 | 34.25 | 27.14 | 25.28 | |
| PBT Margin (%) | 47.95 | 37.74 | 34.23 | 27.10 | 25.24 | |
| Net Profit Margin (%) | 37.44 | 27.59 | 23.98 | 20.58 | 19.59 | |
| Return on Networth / Equity (%) | 32.94 | 34.29 | 34.61 | 35.13 | 36.43 | |
| Return on Capital Employed (%) | 40.39 | 44.37 | 45.17 | 42.13 | 31.95 | |
| Return on Assets (%) | 28.58 | 27.47 | 24.90 | 22.17 | 17.26 | |
| Total Debt/Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | |
| Asset Turnover Ratio (%) | 76.34 | 99.55 | 103.83 | 107.72 | 88.07 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 5.93 | 3.49 | 2.44 | 1.41 | 0.95 | |
| Quick Ratio (X) | 5.58 | 3.20 | 2.12 | 1.18 | 0.80 | |
| Inventory Turnover Ratio (X) | 23.60 | 22.83 | 14.99 | 15.32 | 12.92 | |
| Dividend Payout Ratio (NP) (%) | 16.45 | 0.00 | 0.00 | 0.00 | 20.00 | |
| Dividend Payout Ratio (CP) (%) | 14.96 | 0.00 | 0.00 | 0.00 | 17.22 | |
| Earnings Retention Ratio (%) | 83.55 | 0.00 | 0.00 | 0.00 | 80.00 | |
| Cash Earnings Retention Ratio (%) | 85.04 | 0.00 | 0.00 | 0.00 | 82.78 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 2,077.79 | 2,998.43 | 4,304.12 | 2,856.94 | 1,463.96 | |
| EV/Net Operating Revenue (X) | 3.94 | 5.58 | 10.09 | 8.36 | 6.33 | |
| EV/EBITDA (X) | 7.61 | 13.41 | 26.07 | 26.96 | 22.25 | |
| MarketCap/Net Operating Revenue (X) | 4.05 | 5.67 | 10.16 | 8.59 | 6.61 | |
| Retention Ratios (%) | 83.54 | 0.00 | 0.00 | 0.00 | 79.99 | |
| Price/BV (X) | 3.56 | 7.04 | 14.66 | 14.66 | 12.28 | |
| Price/Net Operating Revenue | 4.05 | 5.67 | 10.16 | 8.59 | 6.61 | |
| Earnings Yield | 0.09 | 0.05 | 0.02 | 0.02 | 0.03 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
24.03.2026
24.03.2026
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth